Lisata Therapeutics (CALADRIUS BIOSCIENCES)

In News

Cancer imaging company buys Lisata for phase 2-stage solid tumor drug - Fierce Biotech

Fierce Biotech - Jan 21, 2026

Lisata reclaims China rights to solid tumor candidate ahead of acquisition - Fierce Biotech

Fierce Biotech - Jan 27, 2026

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics - GlobeNewswire

GlobeNewswire - Sep 15, 2022

2 become 1: Caladrius and Cend merge into tumor-focused Lisata Therapeutics - Fierce Biotech

Fierce Biotech - Apr 27, 2022

Peripheral Artery Disease Market to Showcase Growth at a Paltry CAGR of 4% During the Study Period (2019-2032) | DelveInsight - PR Newswire

PR Newswire - Mar 29, 2023

Caladrius Biosciences to Present at Multiple Upcoming April Conferences - GlobeNewswire

GlobeNewswire - Apr 20, 2016

Lisata lays off 72% of staffers, sues Kuva after planned merger falls apart - Fierce Biotech

Fierce Biotech - Aug 04, 2026

Peripheral Artery Disease Global Market to Surpass USD 54 Billion Mark by 2027 | DelveInsight - PR Newswire

PR Newswire - Aug 24, 2023

Drug-Eluting Balloons Global Market is Expected to Expand at a Healthy Growth Rate of ~8% by 2028, Predicts DelveInsight - PR Newswire

PR Newswire - Jan 24, 2024

CDMO Catalent strengthens ADC pipeline with $10M pact for Lisata tumor drug - Fierce Biotech

Fierce Biotech - Oct 09, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment